To counteract this pathway, we utilized a cell-penetrating peptide specific to ENSA-K63 lactylation, effectively blocking K63 lactylation and consequently inhibiting STAT3 activation in both tumor cells and macrophages. The gene discussed is STAT3; the disease is neoplasm.